For Patients Caregiver Tips and Advice For Medical Professionals

Local Resources

Support groups provide a place for individuals affected by a similar condition or circumstance to provide and receive support and share their experiences.

Not all support groups are facilitated by an American Liver Foundation volunteer. Some support groups are facilitated by 3rd party organizations and individuals in this region.

 


Cambridge, Illinois

Alpha-1 Foundation Support Group – Open Arms Alpha-1 Support Group

Alpha-1 Foundation has over 80 Support Groups Nationwide for Liver and Lung affected Alphas. Please call for more information, including dates and times for support groups or please check www.alpha1.org.

Contact
Jackie English and Deb Burwell (Support Group Leaders)

For more information
http://www.alpha1.org/Alphas-Friends-Family/Support/Support-Groups.

Phone
309-714-9427
309-863-0888

Web
www.alpha1.org

Email
jackieenglish@live.com
openarmsforalpha1@gmail.com

 


Wood Dale, Illinois

Alpha-1 Foundation Support Group – Chicagoland Alpha-1 Support Group

Alpha-1 Foundation has over 80 Support Groups Nationwide for Liver and Lung affected Alphas. Please call for more information, including dates and times for support groups or please check www.alpha1.org

Contact
Dawn Bailey (Support Group Leader)

For more information
http://www.alpha1.org/Alphas-Friends-Family/Support/Support-Groups

Phone
708-774-3529

Web
www.alpha1.org

Email
chicagoalphas@live.com

 


Rockford, Illinois

Alpha-1 Foundation Support Group – Alphas of Northern Illinois

Alpha-1 Foundation has over 80 Support Groups Nationwide for Liver and Lung affected Alphas. Please call for more information, including dates and times for support groups or please check www.alpha1.org

Contact
Mike Dobbs (Support Group Leader)

For more information
http://www.alpha1.org/Alphas-Friends-Family/Support/Support-Groups

Phone
815-222-9081

Web
www.alpha1.org

Email
mjsd2001@msn.com

 


Chicago, Illinois

Andersonville Support Group

First Evangelical Church
5255 North Ashland Avenue
Chicago, IL

Meets: 7:00PM

Meets the 1st and 3rd Wednesday of each month. Please visit the website above for more information.

Contact Terry Enright for more information.

 


Arlington Heights, Illinois

Northwest Community Healthcare
800 W Central Rd, Mallard Room
Center for Specialty Medicine, LCI
Arlington Heights, IL

Meets: First Monday of each month, 7:00 – 9:00 PM

Hep C outreach is a support group for people and/or family and friends of people with Hepatitis C. The group can provide emotional support and share information about the disease with people who have or have had Hepatitis C.

Contact Debra Panarese for more information.

Phone: 847-253-8866
Email: deb72157@comcast.net

 


Springfield, Illinois

Central Illinois Transplant Support Group

4001 Sandhill Road, #124
Springfield, IL 62702

Phone: 217-899-8036

 


Hepatitis C Teleconferences on Tuesday nights

Meets: Tuesday from 7pm to 9pm CST

Listen to speakers discuss various hepatitis C related topics,
followed by a question and answer session, and time to “chat.”
Teleconference is free and confidential.

Web: http://www.hepcmo.org

 


Chicago, Illinois

Liver Support Group at Rush University Medical Center

937 North Atrium classroom
1653 W. Congress Pkwy
Chicago, IL

Meets: Thursdays 3pm

This support group is for patients and their families who are waiting or recovering from liver transplant at Rush. The support group shares stories with one another and is facilitated by a chaplain and social worker. Call Carla Albergo, LSW, (312) 563-4223, with any questions.

 


East Moline, Illinois

New Beginnings – A support group for individuals living with liver disease

Contact Martin Schmidt for more information.

Phone: 309-792-1485

 


Chicago, Illinois

New Hepatitis C Support Group Hosted by the University of Chicago and ALF

Crown Plaza Hotel
160 E. Huron
University of Chicago clinic; 9th floor
Chicago, IL 60611

Meets: January 10, 2013

Contact Jacqueline Dominguez (American Liver Foundation) for more information.

Phone: 312-377-9030
Email: jdominguez@liverfoundation.org

 


Naperville, Illinois

Organ Transplant Support, Inc.

PO Box 471
Naperville, IL 60566

Contact: Carol Olash, President
Phone: 630-527-8640
Email: organtransplantsupport@gmail.com
Website: organtransplantsupport.org
Facebook; OTS Friends

 


Chicago, Illinois

Transplant Support Group

47 W Polk Street, Suite 100-140
Chicago, IL

Phone: 800-494-4527

 


McHenry, Illinois

Transplant Support Group of Northern Illinois

Northern Illinois Medical Center
4201 MEDICAL CENTER DRIVE
McHenry, IL 60050

Phone: 815-477-9528

 


Winfield, Illinois

Support Group

Central DuPage Hospital
25 N. Winfield Rd
Winfield, IL

Meets: First Thursday of each month, 7:00 – 8:30 PM

Provides support for individuals and their family members who have experienced liver disease regardless of type or stage.

Contact Kelly Hofmann for more information.

Phone: 630.399.5709
Email: mth2@att.net

Support groups provide a place for individuals affected by a similar condition or circumstance to provide and receive support and share their experiences.

Not all support groups are facilitated by an American Liver Foundation volunteer. Some support groups are facilitated by 3rd party organizations and individuals in this region.

 


Detroit, Michigan

Alpha-1 Foundation Support Group – East Side Alphas

Alpha-1 Foundation has over 80 Support Groups Nationwide for Liver and Lung affected Alphas. Please call for more information, including dates and times for support groups or please check www.alpha1.org

Contact
Jeannette Therrian (Support Group Leader)

For more information
http://www.alpha1.org/Alphas-Friends-Family/Support/Support-Groups

Phone
248-736-5804

Web
www.alpha1.org

Email
jltherrian@live.com

 


Grand Rapids, Michigan

Alpha-1 Foundation Support Group – Alphas Ganders of West Michigan

Alpha-1 Foundation has over 80 Support Groups Nationwide for Liver and Lung affected Alphas. Please call for more information, including dates and times for support groups or please check www.alpha1.org

Contact
Barbee Bennington (Support Group Leader)

For more information
http://www.alpha1.org/Alphas-Friends-Family/Support/Support-Groups

Phone
855-351- 6610

Web
www.alpha1.org

Email
bbennington@alpha1.org

 


Troy, Michigan

Metro Detroit Hepatitis C Support Group

Location
Boulon Park Outdoor Pavillion
3671 Crooks Road
Troy, MI 48084

Meets
The second Wednesday of every month at 6:30-8pm

Phone
248-321-4176

Web
www.facebook.com/groups/MetroDetroitHCV

Email
robert.wilson@acariahealth.com

 


Huntington Woods, Michigan

Detroit & Suburbs Hepatitis C Support Group

Huntington Woods Library
Lower Level – Friends Room
26415 Scotia Road
Huntington Woods, MI 48070

Meets: Second Wednesday monthly 7-8:30pm

Contact Marcus Calfin for more information.

Phone: 248-672-7561
Email: marcuscal@yahoo.com

 


Detroit, Michigan

Detroit – Henry Ford Hospital Liver Transplant Support Group

Henry Ford Hospital
2799 W. Grand Blvd.
Clinic Building 16th Floor
Detroit, MI 48202

Meets: Second Thursday monthly 11am, Large Conference Room, 16th Floor

Contact Maria Munoz, MSW for more information.

Phone: 313-916-1352
Email: mmunoz2@hfhs.org

 


Royal Oak, Michigan

Transplant Connection – Beaumont Hospital

Beaumont Hospital
Administration Building Royal Oak Campus
Royal Oak, MI 48073-6769

Meets: Meets every 3rd Wednesday of the month at 7:00 pm

Transplant Connection Support Group meets the 3rd Wednesday of each month at Beaumont’s Royal Oak Campus in the Administration Building 1st floor Conference dining rooms A & B. The group is for both pre and post liver transplant patients, their families, friends and caregivers.

Contact Tony Grunkemeyer for more information.

Phone: 248-551-1033 option 3
Email: LLLiver1@sbcglobal.net


Find a Clinical Trial anywhere…

Participating in a clinical trial is a great way to contribute to curing, preventing and treating liver disease and its complications. Start your search here to find clinical trials that need people like you.


NAFLD/NASH Clinical Trial

Northwestern Memorial, Chicago, IL

Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic steatohepatitis (NASH) are the leading causes of chronic liver disease in the Western World. Unfortunately, there are currently no FDA approved treatments for NAFLD/NASH (including patients with cirrhosis), but new treatments are on the horizon! Northwestern University is actively enrolling patients with NAFLD and NASH in numerous clinical drug treatment trials (clinicaltrials.gov).

If you or your patients have a diagnosis of NAFLD/NASH please contact: Dr. Mary Rinella, the study coordinator Stasha Milosevic 312-694-0326, or Kim Sipich 312-694-1293 to obtain more information.

 


Liver Research and Clinical Trials

Northwestern Memorial, Chicago, IL

As a premier academic medical center, Northwestern Memorial and its collaborative partner Northwestern University Feinberg School of Medicine are committed to the advancement of healthcare through clinical innovation, medical education and scientific research.

Our physicians participate in a wide range of clinical trials to improve the treatment of patients with liver disease including, acute/chronic liver failure, auto-immune hepatitis, HCC, Hepatitis B, Hepatitis C, NASH, PBC, PSC. To find out if a research trial is being conducted that fits your needs, please call one of the following study coordinators to assist you:

Jeanne Gottstein 312-694-0264, or Noreen Khan 312-694-1295.


NAFLD/NASH Clinical Trial

Northwestern Memorial, Chicago, IL

Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic steatohepatitis (NASH) are the leading causes of chronic liver disease in the Western World. Unfortunately, there are currently no FDA approved treatments for NAFLD/NASH (including patients with cirrhosis), but new treatments are on the horizon! Northwestern University is actively enrolling patients with NAFLD and NASH in numerous clinical drug treatment trials (clinicaltrials.gov).

If you or your patients have a diagnosis of NAFLD/NASH please contact: Dr. Mary Rinella, the study coordinator Stasha Milosevic 312-694-0326, or Kim Sipich 312-694-1293 to obtain more information.

 


Simvastatin in Preventing Liver Cancer in Patients with Liver Cirrhosis

Northwestern University

This study will test the effects of simvastatin in people with liver cirrhosis. Participants in this study will get either simvastatin or placebo, a pill that looks like the study drug but contains no medication. This will allow researchers to see if participants taking simvastatin show changes in their liver, which may indicate a lower risk of developing cancer. This study is looking for volunteers who are 18 years of age or older and have liver cirrhosis. We will enroll 80 participants.

Contact Kim Sipich at 312-694-1293 or visit our website to obtain more information.


Find a Clinical Trial anywhere…

Participating in a clinical trial is a great way to contribute to curing, preventing and treating liver disease and its complications. Start your search here to find clinical trials that need people like you.


Acute Liver Failure

The aim of this study is to gather prospective demographic and clinical data on Acute Liver Failure patients with varying etiologies. Blood samples, clinical data and survival will be obtained x 7 days.

Contact Information
Angela Liu
University of Michigan
Phone: 734-936-4886
Email Address: angeliu@med.umich.edu

 


Drug-Induced Liver Injury

The goal of this protocol is to create a database and bank of biological specimens (DNA, plasma, lymphocytes) from individuals with severe drug-induced liver injury (DILI) due to isoniazid (INH), phenytoin (Dilantin), amoxicillin /clavulante (Augmentin) or valproic acid (Depakote) after January 1, 1994.

Contact Information
Kristin Chesney, Study Coordinator
University of Michigan
Phone: 734-936-4886
Phone: 866-UM-LIVER
Email: kches@med.umich.edu

 


Role of Pioglitazone (Actos) for the treatment in Chronic Hepatitis C

A study of Pioglitazone vs. Placebo given along with Standard Hepatitis C Treatment (pegylated protein used by the body to fight infection. It is prescribed as an injected medication for people with hepatitis B or hepatitis C.

Insulin resistance (IR), a key factor in the development of fatty liver (steatosis), liver cell injury and scarring (fibrosis) is common in patients with hepatitis C virus (HCV) infection. Recent data suggests that IR and steatosis may lead to progression of liver disease and lower response to treatment especially in hepatitis C especially in genotype 1 infection.

In this study, we will be testing whether the addition of an insulin sensitizing medication (pioglitazone or Actos) to standard antiviral therapy (pegylated interferon ribavirin) will result in improving IR and liver injury in patients with HCV genotype 1 infection. The study involves out-patient visits every four to eight weeks for lab draws and follow-up. A repeat liver biopsy will be done after completing treatment to look for improvement of NASH. We will also study whether this will improve response to treatment in achieving virus eradication (sustained virological response).

Main Inclusion (Eligibility) Criteria

  • Previously untreated (treatment naïve) HCV genotype 1 patients with a liver biopsy done within 6 months of enrollment (others may require a repeat biopsy).
  • Insulin resistance based on HOMA index value (HOMA-IR) of >2.0 during screening

Main Exclusion Criteria

  • Evidence of cirrhosis on liver biopsy
  • Diabetes Mellitus
  • Human immunodeficiency virus (HIV) vaccine or coming into contact with a virus. They protect the body against future infections.

Costs for the Patient
The drugs pegylated interferon ribavirin and the study medication (pioglitazone or placebo) will all be provided free of charge along with certain blood tests that are done for the purposes of the research study. If a patient needs a repeat biopsy to enroll into the study this will be covered by the study. The costs of certain blood tests done as part of standard treatment will be billed to their insurance.

Contact Persons
Please contact Donna Harsh at (734) 763-6647 [e-mail: dharsh@med.umich.edu] or Dr. Hari Conjeevaram at (734) 615-9759 [e-mail: omsairam@med.umich.edu] if you have any questions.

 


Studies in Drug – Induced Liver Injury

I. Idiosyncratic Liver Injury Associated with Drugs (ILIAD)
The goal of the ILIAD protocol is to create a database and bank of biological specimens (DNA, plasma, lymphocytes) from individuals with severe drug-induced liver injury (DILI) due to isoniazid (INH), phenytoin (Dilantin), amoxicillin/ clavulanate (Augmentin), or valproic acid (Depakote) after January 1, 1994. This study is funded by the NIH/ NIDDK.

Study Design

  • Telephone or personal interview of medical history surrounding DILI event
  • Single blood draw
  • Participant receives $75

Please contact Kristin Chesney at (734) 936-4886, toll free 1-866-UM-LIVER, or kches@med.umich.edu or Robert Fontana rfontana@umich.edu for referrals or questions.

II. A Multi-Center, Longitudinal Study of Drug- and CAM-Induced Liver Injury
The goal of this NIH study is to prospectively identify bona fide cases of liver injury due to drugs and complementary and alternative medications (CAM) within 6 months of onset. Clinical data, blood, DNA, and urine will be collected from affected patients and matched controls for mechanistic and genetic studies.

Study Design
All subjects have a baseline and 6-month follow-up visit at the University of Michigan which includes: surveys, medical history, blood, and urine collection.
Patients with liver injury at 6 months return for 12 and 24- month visits.

Costs

  • Costs of study lab tests are provided by the sponsor (NIDDK).
  • Subjects receive $50 for each completed study visit.

Contact
Please contact Kristin Chesney at (734) 936-4886, toll free 1-866-UM-LIVER, kches@med.umich.edu, or Robert Fontana rfontana@umich.edu for referrals or questions.

 


University of Michigan Health System – Hepatitis C Clinical Research Study

Role of Pioglitazone (Actos) treatment in Chronic Hepatitis C
Insulin resistance (IR), a key factor in the development of hepatic steatosis, liver cell injury and fibrosis is common in patients with hepatitis C virus (HCV) infection. An association between steatosis and fibrosis has been emphasized in HCV infection. Available studies to date including our own suggest an important role of IR and steatosis in the pathogenesis of liver disease and response to antiviral therapy especially in type 1 infection.

University of Michigan will be testing the hypothesis that in patients with genotype 1 infection, the addition of an insulin sensitizing agent such as pioglitazone to standard antiviral treatment regimen will result in a greater reduction of insulin resistance (IR) and hepatic steatosis compared to antiviral treatment alone. U of M will be testing whether improvement in IR will result in improvement in inflammation and possibly the rate of sustained virological response (SVR) in patients with chronic hepatitis C and genotype 1 infection.

Inclusion criteria

  • Males and females: age greater than 18 years of age.
  • HCV genotype 1 patients with evidence of chronic hepatitis with a minimum fibrosis score of 1 on liver biopsy done within 6 months of enrollment.
  • Insulin resistance based on HOMA index value (HOMA-IR) of >2.0 during screening.
  • Able and willing to provide written informed consent.

Exclusion criteria

  • Hepatitis C patients who underwent previous therapy for their liver disease
  • Genotype other than type 1. Histological evidence of cirrhosis or confirmed hepatocellular carcinoma (HCC).
  • Evidence of other causes of chronic liver disease.
  • Diabetes Mellitus.
  • Medications that lead to hepatic steatosis including such as amiodarone, systemic steroids, tamoxifen, valproic acid, and methotrexate.
  • Human immunodeficiency virus (HIV) antibody positive.
    Patients with solid organ transplants.
  • Pregnancy or breast feeding.
  • Participation in any other clinical trial within 90 days of entry into this trial.
  • Unwilling to consent for the study.

Contact Information
Donna Harsh, M.S. Research Coordinator
University of Michigan Heath Center
Ann Arbor, MI
Phone: 734-763-6647
Fax: 734-936-7392
Email Address: dharsh@med.umich.edu

 


Wilson’s Disease

This randomized double blind study is conducted to compare efficacy and toxicity of three anti-copper drugs, penicillamine, trientine and tetrahiomolybdate for the initial treatment of Wilson’s disease patients presenting with liver disease. The objective of the study is to compare rate and degree of recovery of liver function and to compare side effects.

The treatment period is 24 weeks, the first 6 weeks of which are spent in the General Clinical Research Center of the University of Michigan Hospital, with free medical care and hospitalization provided to the extent required for Wilson’s disease. The next 18 weeks involves home treatment, with the appropriate anti-copper medication provided. It will be necessary to have blood tests every 2 weeks during the 18 week period at home with the results sent to us. The blood tests involve blood counts and liver function tests, readily available anywhere. Patients will be followed with the referring physician, as desired. Patients will be responsible for travel costs to Ann Arbor and for blood tests during the last 18 weeks.

Contact Information
Fred Askari, MD, PhD
University of Michigan
Phone: 734-647-2964

Interested in free hepatitis C screenings in an area near you? Here are upcoming dates and locations of hepatitis C screenings in the area! Know your status!

Learn more about testing and resources in your area with this CDC database of free screenings by zip code! Click here!

Weekly Testing by M.A.D.E (Making a Daily Effort)

Mondays, 9am – 2pm

  • 8000 S. Cottage Grove

Tuesdays, 9am – 2pm

  • 5343 S. Western

Wednesdays and Thursdays, 9am – 2pm

  • 5959 S Ashland

Weekly Testing by BHC (Brothers Health Collective)

Tuesdays, Thursdays, Saturdays, 10 am – 2pm

  • Matthew House Chicago, 3722 S Indiana Ave

4th Fridays of the month, 10 am – 2 pm

  • Chicago Women’s AIDS Project 6363, N Broadway St

Saturdays, 9 am – 3 pm

  • 2517 S Archer Ave

The Night Ministry

The Night Ministry Mobile Screening Van (Note: the Night Ministry only serves 1. Those experiencing homelessness or unstable housing, 2. MSM of color)

Sunday

  • Humboldt Park (Division & California) 4:00 – 6:00 pm
  • Uptown (Wilson & Hazel) 6:30 -8:30 pm

Monday

  • South Shore (Jeffery & 71st) 7:00 – 9:00 pm
  • Pilsen (Cermak & Loomis) 9:30 – 11:30 pm


Tuesday

  • Back of the Yards (54th & Halsted) 7:00 – 9:00 pm
  • Humboldt Park (Division & California) 9:30 – 11:30 pm

Wednesday

  • South Shore (Jeffery & 71st) 7:00 – 9:00 pm
  • Uptown (Wilson & Hazel) 9:45 -11:45 pm

Thursday

  • Back of the Yards (54th & Halsted) 7:00 – 9:00 pm
  • Pilsen (Cermak & Loomis) 9:30 – 11:30 pm

Join ALF for our monthly webinar series on a variety of topics relating to liver wellness!

Contact: Sarah Koltun (Email)
Phone: 312-377-9030

Each webinar will be released on the 1st of the month. Participants can then leave questions and comments for the following 2 weeks. After this period, the speaker will follow up to address any questions and comments.

Upcoming Webinars

  • September: Obesity
  • October: Know your Liver
  • November: Alcohol
  • December: Health Insurance
Managing Medications with Liver Disease

Managing Medications with Liver Disease

July is Disease Management Month for the Get Fit program! Check out our webinar of the month: Managing Medications with Liver Disease Presented by: Mia Schmiedeskamp-Rahe, PharmD, University of Illinois Health Sponsored By: ...

State of Illinois Department of Insurance
Download brochure


Share this page
Facebooktwittergoogle_pluspinterestlinkedinmailFacebooktwittergoogle_pluspinterestlinkedinmail

Visit Us On FacebookVisit Us On TwitterVisit Us On InstagramVisit Us On YoutubeVisit Us On Linkedin